Scientists explain why magic mushrooms can combat Parkinson's disease
When I hear the words 'magic mushrooms,' I imagine a group of indie-looking teenagers micro-dosing at a festival.
An estimated eight million American adults used psilocybin in 2023, according to figures from RAND.
Whether it's used to enhance some sort of guided meditation, or to experience some life-changing epiphanies in the park with your friends one sunny day, it's been proven the psychedelic drug - called psilocybin - can help with anxiety and depression.
However, researchers from the University of California San Francisco (UCSF) have seen some incredible results after trialing the drug with Parkinson's disease patients.
The condition mainly affects people over the age of 50 and occurs when parts of the brain become progressively damaged over time.
Its symptoms include involuntary shaking or tremors, muscle stiffness and anxiety and depression.
The study is the first of its kind to test the effects of psychedelics on patients with a neurodegenerative disease.
Parkinson's is the second-most common neurodegenerative disease after Alzheimer's. Nearly one million people in the US are living with the condition, the Parkinson's Foundation reports - a figure that's expected to rise to 1.2 million in the next five years.
The groundbreaking pilot study, saw 12 patients with 'mild to moderate' Parkinson's receive two doses of psilocybin: 10 mg, followed by 25 mg two weeks later.
They also underwent regular psychotherapy sessions to track their wellbeing.
The study's aim was to assess the safety of psilocybin, yet the results uncovered something unexpected - and pretty incredible.
Participants experienced significant, lasting improvements in mood, cognition and motor function, which persisted for weeks after the drug had left their systems. These mental health improvements were reported for up to three months after their final dose of the drug. Scientists reckon this could be chalked up to two major reasons.
Firstly, psilocybin's impact on patient's mood could've led to better cognitive and motor functions.
This, in turn, would've helped them socialize and become more active - both key elements of Parkinson's treatment.
Another is that psilocybin could reduce inflammation and promote neuroplasticity, which is the growth and reconnection of brain cells involved in mood, cognition, and movement regulation.
'We are still in very early stages of this work, but this first study went well beyond what we expected,' said the paper's first author, Ellen Bradley, MD, assistant professor and associate director of UCSF's Translational Psychedelic Research Program (TrPR).
'Many people don't realize this, but mood symptoms in Parkinson's are linked to a faster physical decline,' she said. 'And they are actually a stronger predictor of patients' quality of life with Parkinson's than their motor symptoms.'
Encouraged by the results, UCSF is set to launch a larger, randomized trial in partnership with Yale, aiming to enrol 100 participants.
This next phase will incorporate brain imaging and other tools to understand psilocybin's effects on brain function in more detail.
'The vast majority of brain diseases lack treatments that change their course,' said Dr. Joshua Woolley, senior author. 'These results raise the exciting possibility that psilocybin may help the brain repair itself.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 minutes ago
- Yahoo
The impact of Medicaid, SNAP cuts in Trump's ‘big, beautiful bill'
ST. LOUIS – Last week, the nonpartisan Congressional Budget Office (CBO) issued its analysis of President Donald Trump's so-called 'big, beautiful bill.' The CBO predicted the legislation would increase the federal deficit by $2.4 trillion over the next decade and leave nearly 11 million people without health insurance. 'They're asking the poorest Americans to tighten their belts, so that the richest Americans can loosen their belts, and that's what makes it so extra unfair,' Bobby Kogan, senior director of federal budget policy at the Center for American Progress, said. Kogan says the president's tax bill could feature the largest Medicaid and Supplemental Nutrition Assistance Program (SNAP) cuts in history. 'By putting up so much red tape, tons of people who're doing everything right fall through the cracks,' Kogan said. 'These are incredibly meager benefits and all of the sudden, lots of people are going to lose them.' Police crackdown on reckless, disabling dozens of cars Kogan says the bill freezes Medicaid provider taxes, which many states use to help pay for large portions of their Medicaid programs. 'Already, a lot of hospitals are struggling, and this would definitely make the situation much worse,' he said. Senator Josh Hawley warned this could force rural hospitals to close. 'You've got some senators who now want to change this bill to cut Medicaid benefits. That's ridiculous. That's insane. 1.3 million people in Missouri are on Medicaid, including hundreds of thousands of kids. These are working people who cannot afford health insurance otherwise,' Hawley said in a June 5 interview. Last week, Hawley posted on his X social media account, 'Just had a great talk with President Trump about the big, beautiful bill. He said again, no Medicaid benefit cuts.' 'Failure is not an option. And we intend to deliver, along with the president, for the American people,' Senate Majority Leader John Thune, R-S.D., said. With Senate Republicans planning to get the bill to the president's desk by July 4, Kogan fears the fallout. 'There's a lot at stake here and a lot of people's livelihoods could be upended, so I hope the senators could see differently,' Kogan said. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
17 minutes ago
- Yahoo
Common Childhood Virus Linked to Alzheimer's Development in Old Age
A study published 30 years ago is striking up new conversation about the potential connection between the common cold sore and Alzheimer's disease. Published in The Lancet in 1997, researchers compared DNA extracted from the brains of elderly people with and without Alzheimer's, and in some of them, found herpes simplex virus 1 (HSV-1)—an infection often contracted in childhood—dormant in the nerves. Ultimately, researchers predicted that those with HSV-1 and a specific gene, called the ApoE-e4 gene, had a higher risk of developing Alzheimer's. Meet the Experts: David Hunter, M.D., an assistant professor and neurologist with UTHealth Houston, Linda Yancey, M.D., an infectious disease doctor at Memorial Hermann Health System; and Mark Santos, Ph.D., an assistant professor of microbiology and immunology at Touro University Nevada. Study co-author Ruth Itzhaki, Ph.D., summarized her team's findings in a recent article for The Conversation and noted that, over the years, additional work has surfaced to support hers. But what does it all mean, exactly? If a cold sore pops up, should you be concerned about dementia? We reached out to experts who explained everything. 'HSV-1 is a common virus to which almost everyone is exposed early in life,' says David Hunter, M.D., an assistant professor and neurologist with UTHealth Houston. 'It is best known for causing cold sores and is closely related to chicken pox and mononucleosis.' What these viruses have in common is that they are neurotropic, meaning they linger in the nervous system long after the initial illness, explains Linda Yancey, M.D., an infectious disease doctor at Memorial Hermann Health System, and can be reactivated by stress or lowered immunity. That's how, for instance, chicken pox can manifest later in life as shingles, adds Dr. Hunter. The virus's ability to infiltrate the nerves is believed to get it past the blood-brain barrier, a membrane that shields the organ from infection via the bloodstream. Thanks to that entry point, Dr. Hunter says, HSV-1 is the most common cause of viral brain inflammation in the United States. 'There is no vaccine for HSV and almost everyone will get it by adulthood,' Dr. Hunter adds. Cold sores are a mild case of it, and symptoms can be treated with antiviral drugs. Dormant HSV-1 may be reactivated by illness and reach the brain, explains Mark Santos, Ph.D., an assistant professor of microbiology and immunology at Touro University Nevada. This can trigger brain inflammation over time, known as herpes encephalitis,and in people with genetic risk factors, like the ApoE-4 gene, contribute to Alzheimer's development, he adds. 'We don't entirely know why ApoE-4 is a risk factor for Alzheimer's,' adds Dr. Hunter. 'The link to HSV could be that ApoE-4 impacts the blood-brain barrier and makes it easier for HSV to enter.' And the inflammation caused by that entry may heighten Alzheimer's risk. 'It is now universally accepted that inflammation in the brain is a key step in the development of Alzheimer's,' Dr. Hunter reiterates. In the three decades since the original study, doctors and researchers have learned much more about Alzheimer's disease and its connection to viral inflammation. For instance, several studies have found that being immunized for any disease (like COVID-19 or the flu) reduces Alzheimer's risk, says Dr. Hunter. 'Several other studies have shown that reducing inflammation in the brain helps prevent Alzheimer's,' he adds. Santos concurs. 'Since 1996, additional studies have found HSV-1 DNA in the brains of individuals with Alzheimer's. Lab studies have also shown that HSV-1 infection can trigger the buildup of amyloid-beta and tau—proteins strongly associated with Alzheimer's pathology,' he explains. However, there are a few disclaimers to note. Firstly, the posed risk is associated with people who contract HSV-1 in early life, giving it time to progressively cause inflammation. The risk may be lower in adults, says Santos. 'That said, if someone has other risk factors (like a weakened immune system or APOE-e4), adult-onset HSV-1 could still have long-term consequences,' he adds. Still, neurotropic viruses are extremely common, Dr. Yancey reiterates. 'This makes it difficult to tease out whether they are causing neurologic problems or are simply common in the general population, including people with neurologic problems,' she adds. In other words, because most people end up with HSV-1 doesn't necessarily mean that most people will get Alzheimer's. 'Most cold sores aren't a cause for concern,' Santos adds. 'They're common and usually well-controlled by the immune system. But for people with frequent outbreaks, weakened immunity, or APOE-e4, it may be worth discussing with a healthcare provider. The concern is not a single cold sore, but long-term viral activity in the brain.' More research, including long-term studies, is needed to make any solid associations, Santos and Dr. Yancey conclude. 'The current data is based on population-level surveys. There is no way to predict on an individual patient's level whether this has a meaningful impact,' says Dr. Yancey. Future research will, hopefully, at least help experts understand how antiviral treatment affects Alzheimer's risk, as well as identify better ways to detect when HSV-1 is active in the brain. 'The hope is that understanding how infections contribute to Alzheimer's will open up new ways to prevent or treat it—especially before symptoms start,' says Santos. Being vaccinated, exercising, engaging in mental stimulation, and maintaining a heart-healthy diet are all known ways to lower dementia risk, our experts say. Avoiding smoking or nicotine use of any kind can also 'drastically' reduce the risk, says Dr. Yancey. All of these habits and choices work together to support both immune and brain health. You Might Also Like Can Apple Cider Vinegar Lead to Weight Loss? Bobbi Brown Shares Her Top Face-Transforming Makeup Tips for Women Over 50
Yahoo
42 minutes ago
- Yahoo
RFK Jr sacks entire US vaccine committee
US Health Secretary Robert F Kennedy Jr, a vaccine sceptic, has removed all 17 members of a committee that issues official government recommendations on immunisations. Announcing the move in an editorial in the Wall Street Journal, Kennedy said that conflicts of interest on the Advisory Committee on Immunization Practices (Acip) were responsible for undermining trust in vaccinations. Kennedy said he wanted to "ensure the American people receive the safest vaccines possible." Doctors and health experts have criticised Kennedy's longstanding questioning of the safety and efficacy of a number of vaccines, although in his Senate confirmation hearing he said he is "not going to take them away." On Monday he said he was "retiring" all of the Acip panel members. Eight of the 17 panellists were appointed in January 2025, in the last days of President Biden's term. Most of the members are practicing doctors and experts attached to major university medical centres. Kennedy noted that if he did not remove the committee members, President Trump would not have been able to appoint a majority on the panel until 2028. "The committee has been plagued with persistent conflicts of interest and has become little more than a rubber stamp for any vaccine," Kennedy wrote. He claimed that health authorities and drug companies were responsible for a "crisis of public trust" that some try to explain "by blaming misinformation or antiscience attitudes." In the editorial, Kennedy cited examples from the 1990s and 2000s and alleged that conflicts of interest persist. "Most of ACIP's members have received substantial funding from pharmaceutical companies, including those marketing vaccines," he wrote in the Wall Street Journal. The move appears contrary to assurances Kennedy gave during his confirmation hearings. Bill Cassidy, a Republican Senator from Louisiana who is also a doctor, reported that he received commitments from the health secretary that Acip would be maintained "without changes." On Monday, Cassidy wrote on X: "Of course, now the fear is that the Acip will be filled up with people who know nothing about vaccines except suspicion. "I've just spoken with Secretary Kennedy, and I'll continue to talk with him to ensure this is not the case." Acip members are required to disclose conflicts of interest, which are posted online, and to recuse themselves from voting on decisions where they may have a conflict. "The problem isn't necessarily that ACIP members are corrupt," Kennedy wrote. "Most likely aim to serve the public interest as they understand it. "The problem is their immersion in a system of industry-aligned incentives and paradigms that enforce a narrow pro-industry orthodoxy." Dr Bruce Scott, president of the American Medical Association, a professional organisation for American doctors, said mass sacking "upends a transparent process that has saved countless lives." "With an ongoing measles outbreak and routine child vaccination rates declining, this move will further fuel the spread of vaccine-preventable illnesses," Dr Scott said in a statement. Kennedy did not say who he would appoint to replace the board members. Acip has a meeting scheduled starting 25 June, at which members are scheduled to vote on recommendations for vaccines for Covid, flu, meningococcal disease, RSV and other illnesses. The BBC contacted the US Department of Health and Human Services and the Acip chair, Dr Helen Keipp Talbot, for comment. Fact-checking RFK Jr's views on health policy The two faces of Robert F Kennedy Jr
